Newsroom Bayer

September
21,
2023
| 10:59 AM Europe/Amsterdam
Agreement with UK-based NIAB to acquire their strawberry pipeline and commercial portfolio / Focus on large-scale professional strawberry growers to meet growing consumer and retail demand / The program will continue to be based in Kent,
September
21,
2023
| 08:59 AM Europe/Amsterdam
Climate impacts estimated to have reduced farmer incomes by 15.7% on average over the past two years / Most pressing short-term challenges dominated by economic uncertainty and cost concerns / Yet 4 in 5 farmers have already taken or plan to take
September
21,
2023
| 08:29 AM Europe/Amsterdam
The investment supports Bayer’s sustainability goal to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030 / The company’s facility in Turku will utilize automation, robotics, and digital
September
20,
2023
| 17:59 PM Europe/Amsterdam

Bayer issues 1.75 billion euro hybrid bond

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds
September
19,
2023
| 08:59 AM Europe/Amsterdam
Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States.
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform /
August
30,
2023
| 14:59 PM Europe/Amsterdam

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

Strong commitment to modern Crop Protection made in Europe:

Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m gross floor area / R&D facility offers space for 200
August
29,
2023
| 13:59 PM Europe/Amsterdam
New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s
August
28,
2023
| 07:59 AM Europe/Amsterdam
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year, exploratory clinical endpoints improved overall, with
August
24,
2023
| 10:29 AM Europe/Amsterdam
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF)
August
22,
2023
| 13:59 PM Europe/Amsterdam
Berlin, August 22, 2023 – Bayer today announced Juergen Eckhardt MD, MBA as the new Head of Business Development & Licensing / Open Innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. He will join the Pharmaceuticals

Sign up for our Newsletter

We will keep you informed about the latest news.